{"product_id":"siga-vrio-analysis","title":"SIGA Technologies, Inc. (SIGA): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eIs SIGA Technologies, Inc. (SIGA) truly built for the long haul? This concise VRIO analysis cuts straight to the core, revealing precisely where its competitive edge lies - or where it's missing - across Value, Rarity, Inimitability, and Organization. Dive in below to see the distilled verdict on SIGA Technologies, Inc. (SIGA)'s path to sustainable success.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eSIGA Technologies, Inc. (SIGA) - VRIO Analysis: 1. TPOXX Regulatory Approvals \u0026amp; Formulation Breadth (Oral\/IV)\n\u003c\/h2\u003e\n\n\u003cp\u003eYou’re looking at the core moat for SIGA Technologies, Inc. (SIGA): the dual-formulation approval for TPOXX. This isn't just about having a drug; it's about having the right delivery mechanism for every contingency, which is why the U.S. government keeps buying it.\u003c\/p\u003e\n\n\u003cp\u003eThe value here is crystal clear, demonstrated by actual procurement dollars. For the nine months ended September 30, 2025, oral and IV sales to the U.S. Strategic National Stockpile (SNS) totaled \u003cstrong\u003e$79 million\u003c\/strong\u003e. That number shows the market values having both an oral capsule for general use and an IV formulation for critically ill or non-swallowing patients. Also, international sales added another \u003cstrong\u003e$6 million\u003c\/strong\u003e in oral TPOXX revenue over that same nine-month period.\u003c\/p\u003e\n\n\u003cp\u003eHere’s the quick math on the 9M 2025 product revenue breakdown:\u003c\/p\u003e\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eFormulation\/Customer\u003c\/td\u003e\n    \u003ctd\u003eRevenue (9M Ended Sept 30, 2025)\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eOral TPOXX (U.S. SNS\/Govt)\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e$53 million\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eIV TPOXX (U.S. SNS\/Govt)\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e$26 million\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eOral TPOXX (International)\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e$6 million\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eTotal Product Revenue\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e$85.8 million\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cp\u003eWhat this estimate hides is the Q3 volatility, but the nine-month trend confirms the core asset's strength.\u003c\/p\u003e\n\n\u003cp\u003eRarity is high because securing U.S. Food and Drug Administration (FDA) approval for a novel antiviral against a rare threat like smallpox is tough. Having both the oral form (approved 2018) and the IV form (approved May 2022) makes SIGA a significantly rarer player than competitors with only one option. Plus, the January 2025 approval of TEPOXX in Japan further solidifies this unique global regulatory footprint.\u003c\/p\u003e\n\n\u003cp\u003eImitability is defintely high. Replicating this asset means navigating years of clinical trials and regulatory hurdles for two distinct formulations against a low-frequency, high-consequence pathogen. It’s a massive barrier to entry. Organizationally, SIGA manages this complexity well, which is crucial.\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eManage separate supply chains for oral\/IV.\u003c\/li\u003e\n  \u003cli\u003eMaintain distinct regulatory dossiers globally.\u003c\/li\u003e\n  \u003cli\u003eSecure ongoing government procurement contracts.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe resulting competitive advantage is sustained. This combination of approved, ready-to-deploy formulations for a critical biodefense countermeasure is a powerful, hard-to-replicate asset that underpins SIGA’s profitability, evidenced by the \u003cstrong\u003e$33.2 million\u003c\/strong\u003e in pre-tax operating income for the first nine months of 2025.\u003c\/p\u003e\n\n\u003cp\u003eFinance: review the outstanding $26 million in U.S. government orders targeted for 2026 delivery by end of month.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eSIGA Technologies, Inc. (SIGA) - VRIO Analysis: 2. Exclusive\/Deep U.S. Government Contractual Relationship (BARDA 19C)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Provides a stable, high-volume revenue floor, insulating the company from typical commercial market volatility.\u003c\/p\u003e\n\u003cp\u003eThe product revenues for the three months ended June 30, 2025, totaled approximately \u003cstrong\u003e$79.1 million\u003c\/strong\u003e, comprising \u003cstrong\u003e$53 million\u003c\/strong\u003e of oral TPOXX sales and \u003cstrong\u003e$26 million\u003c\/strong\u003e of IV TPOXX sales delivered to the U.S. Strategic National Stockpile (SNS) under the 19C BARDA contract. For the six months ended June 30, 2025, total product sales reached \u003cstrong\u003e$84.9 million\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eProduct sales for the three months ended June 30, 2025: \u003cstrong\u003e$79.1 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eBreakdown of Q2 2025 SNS deliveries: Oral TPOXX sales of \u003cstrong\u003e$53 million\u003c\/strong\u003e and IV TPOXX sales of \u003cstrong\u003e$26 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eTotal product sales for the nine months ended September 30, 2025: approximately \u003cstrong\u003e$86 million\u003c\/strong\u003e, including \u003cstrong\u003e$53 million\u003c\/strong\u003e oral TPOXX and \u003cstrong\u003e$26 million\u003c\/strong\u003e IV TPOXX under the 19C BARDA contract.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e High. This deep, multi-year partnership with the Biomedical Advanced Research and Development Authority (BARDA) is unique to SIGA for this specific threat area.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High. Competitors cannot easily replicate the trust, history, and established procurement mechanisms built over years with the U.S. government.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High. Management’s focus is clearly aligned with fulfilling and expanding these government orders, as seen by the March 2025 \u003cstrong\u003e$26 million\u003c\/strong\u003e IV TPOXX procurement.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eProcurement order for \u003cstrong\u003e$26 million\u003c\/strong\u003e of IV TPOXX received from the U.S. Government in March 2025 under the 19C BARDA contract, targeted for delivery in 2026.\u003c\/li\u003e\n\u003cli\u003eTotal new development funding awarded under the BARDA 19C Contract during the three months ended June 30, 2025: \u003cstrong\u003e$27 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThis new funding included \u003cstrong\u003e$14 million\u003c\/strong\u003e for manufacturing support activities and \u003cstrong\u003e$13.2 million\u003c\/strong\u003e for the TPOXX pediatric program development.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eContract Metric\u003c\/th\u003e\n\u003cth\u003eValue\/Amount\u003c\/th\u003e\n\u003cth\u003eContext\/Date\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e2018 BARDA Contract Value\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$546 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eTotal potential procurement value.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2018 Contract Exercised to Date\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$520 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePortion of the 2018 contract exercised.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSNS Deliveries from 2018 Contract\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e$440 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eDelivered to the SNS from the 2018 contract.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOutstanding Orders (Mar 31, 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$94 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eTPOXX Orders outstanding to be delivered to the SNS.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBase Period Reimbursed Activities Funding\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e$59.5 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eContemplated payment under the 19C contract base period.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. This relationship is the bedrock of their business model and is protected by institutional inertia.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eSIGA Technologies, Inc. (SIGA) - VRIO Analysis: 3. Strong, Debt-Free Balance Sheet (Cash Position)\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Provides capital for R\u0026amp;D, strategic flexibility, and shareholder returns without the pressure of debt covenants. As of September 30, 2025, SIGA held approximately \u003cstrong\u003e$172 million\u003c\/strong\u003e in cash with no debt.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. Many biotechs carry debt; a large, debt-free cash pile is less common, especially for a commercial-stage firm.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate. While competitors can raise capital, achieving this level of cash reserves without incurring debt takes time and consistent profitability.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High. The company has demonstrated discipline by returning capital, declaring a special cash dividend of \u003cstrong\u003e$0.60\u003c\/strong\u003e per share in April 2025.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. Cash can be spent or eroded by operating losses, but it currently provides a significant buffer.\u003c\/p\u003e\n\n\u003cp\u003eFinancial Metrics Supporting Balance Sheet Strength:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe company declared a special cash dividend of \u003cstrong\u003e$0.60\u003c\/strong\u003e per share in April 2025, payable May 15, 2025.\u003c\/li\u003e\n\u003cli\u003eThis marked the fourth consecutive year of a special cash dividend declaration.\u003c\/li\u003e\n\u003cli\u003eProduct sales for the nine months ended September 30, 2025, were approximately \u003cstrong\u003e$86 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eNet income for the nine months ended September 30, 2025, was around \u003cstrong\u003e$29 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial Metric\u003c\/td\u003e\n\u003ctd\u003eAmount\u003c\/td\u003e\n\u003ctd\u003ePeriod\/Context\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash \u0026amp; Cash Equivalents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$171.96 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eLatest Balance Sheet Data\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Debt\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$914,548\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eLatest Balance Sheet Data\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Cash Position\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$171.04 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eLatest Balance Sheet Data\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Cash Per Share\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2.39\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eLatest Balance Sheet Data\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCurrent Ratio\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e9.17\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eLatest Balance Sheet Data\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDebt \/ Equity Ratio\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e0.00\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eLatest Balance Sheet Data\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue (TTM)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$172.25 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eLast 12 Months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Income (TTM)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$74.47 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eLast 12 Months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eSIGA Technologies, Inc. (SIGA) - VRIO Analysis: 4. Intellectual Property Estate (Core Patents on Tecovirimat)\n\u003c\/h2\u003e\n\n\u003cp\u003eThe intellectual property estate centers on the core patents covering Tecovirimat (TPOXX).\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eContext\/Date Reference\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal US Drug Patents (Filed)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e11\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFiled from 2018 to 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eActive US Drug Patents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e8\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of a recent report\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExpired US Drug Patents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e3\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of a recent report\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Global Patent Family Members\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e96\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAcross \u003cstrong\u003e24\u003c\/strong\u003e countries\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEstimated Earliest Generic Entry Date (US)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eMarch 23, 2031\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eBased on patent\/regulatory analysis\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduct Sales (Year Ended Dec 31, 2024)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$133.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Income (Year Ended Dec 31, 2024)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$59.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch\u003e\u003ch\u003eValue: Creates a legal barrier against generic or competing smallpox\/orthopoxvirus treatments, securing future revenue streams. The IP underpins the entire value of TPOXX.\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eThe value is evidenced by significant revenue generation tied to the product protected by the IP.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eProduct Revenue (Nine Months Ended September 30, 2024): \u003cstrong\u003e$53 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eProduct Sales (Year Ended December 31, 2024): \u003cstrong\u003e$133.3 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eNet Income (Year Ended December 31, 2024): \u003cstrong\u003e$59.2 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch\u003e\u003ch\u003eRarity: Moderate. Patents exist in pharma, but the specific, foundational patents covering this mechanism for this indication are concentrated with SIGA.\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eThe concentration of protection across multiple jurisdictions indicates rarity in scope.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTotal Global Patent Family Members: \u003cstrong\u003e96\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eCountries with Patent Protection: \u003cstrong\u003e24\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch\u003e\u003ch\u003eImitability: High. Competitors must design around or wait for patent expiration, a process that takes years and significant R\u0026amp;D spend.\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eThe time horizon until potential generic entry quantifies the difficulty of imitation.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eEstimated Earliest Generic Entry Date: \u003cstrong\u003eMarch 23, 2031\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eSpecific Patent Expiry Example (US9339466): \u003cstrong\u003eMar, 2031\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eSpecific Patent Expiry Example (US11890270): \u003cstrong\u003e08 Aug, 2032\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch\u003e\u003ch\u003eOrganization: Moderate. The company actively defends its rights, though litigation risk remains a factor.\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eThe company's operational focus and inherent risks related to IP defense are noted.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe company has received procurement orders from \u003cstrong\u003e30\u003c\/strong\u003e countries over the past three years.\u003c\/li\u003e\n\u003cli\u003eRisk factor noted: Any challenge to SIGA's patent rights, 'even if determined favorably, could be costly'.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch\u003e\u003ch\u003eCompetitive Advantage: Sustained. As long as key patents remain in force, the advantage is protected.\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eThe sustained advantage is directly linked to the active patent life.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eActive US Drug Patents: \u003cstrong\u003e8\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eOutstanding Procurement Orders (as of early 2025): Approximately \u003cstrong\u003e$70 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eSIGA Technologies, Inc. (SIGA) - VRIO Analysis: 5. TPOXX Post-Exposure Prophylaxis (PEP) Pipeline Development\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Opens a massive new market segment beyond just stockpiling, potentially increasing the per-unit value and broadening the customer base. They target an FDA submission for PEP in the \u003cstrong\u003efirst half of 2026\u003c\/strong\u003e. This indication would require a \u003cstrong\u003e28-day regimen\u003c\/strong\u003e, versus \u003cstrong\u003e14 days\u003c\/strong\u003e for the treatment indication of TPOXX, and therefore holds \u003cstrong\u003edouble the market potential\u003c\/strong\u003e for the company.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. Other antivirals exist, but securing a successful PEP indication for this threat is a significant, unproven catalyst. For context, SIGA has sold \u003cstrong\u003e$135 million\u003c\/strong\u003e of oral TPOXX to \u003cstrong\u003e30 countries\u003c\/strong\u003e since 2020.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate. Competitors are likely pursuing similar indications for their own antivirals, but SIGA has a head start.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High. The company is actively collaborating with the \u003cstrong\u003eCDC and FDA\u003c\/strong\u003e to advance this program. The PEP program is funded and supported in collaboration with the \u003cstrong\u003eU.S. Department of Defense\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. The advantage is contingent on successful clinical data and regulatory acceptance, which is still pending.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eVRIO Component\u003c\/th\u003e\n\u003cth\u003eAssessment\u003c\/th\u003e\n\u003cth\u003eSupporting Data\/Metric\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eHigh Potential\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e28-day regimen\u003c\/strong\u003e for PEP vs. \u003cstrong\u003e14-day\u003c\/strong\u003e treatment; holds \u003cstrong\u003edouble the market potential\u003c\/strong\u003e.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003eModerate\u003c\/td\u003e\n\u003ctd\u003eInternational sales context: \u003cstrong\u003e$135 million\u003c\/strong\u003e to \u003cstrong\u003e30 countries\u003c\/strong\u003e since 2020.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability\u003c\/td\u003e\n\u003ctd\u003eModerate\u003c\/td\u003e\n\u003ctd\u003eCompetitors pursuing similar indications.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003ctd\u003eActive collaboration with \u003cstrong\u003eCDC and FDA\u003c\/strong\u003e; DoD support.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetitive Advantage\u003c\/td\u003e\n\u003ctd\u003eTemporary (Contingent)\u003c\/td\u003e\n\u003ctd\u003eTargeting FDA submission in \u003cstrong\u003efirst half of 2026\u003c\/strong\u003e.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eRelevant Financial and Statistical Data:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eSIGA ended the second quarter of 2025 with a cash balance of approximately \u003cstrong\u003e$182 million\u003c\/strong\u003e and \u003cstrong\u003eno debt\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eProduct revenues for the second quarter of 2025 were approximately \u003cstrong\u003e$79 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe U.S. government provided an additional \u003cstrong\u003e$27 million\u003c\/strong\u003e in development funding in Q2 2025.\u003c\/li\u003e\n\u003cli\u003eThe company has returned \u003cstrong\u003e$230 million\u003c\/strong\u003e to shareholders via special dividends and share buybacks since 2020.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eSIGA Technologies, Inc. (SIGA) - VRIO Analysis: 6. Global Regulatory Footprint (US, EU, UK, Japan Approvals)\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Allows for international procurement contracts, diversifying revenue away from sole reliance on the U.S. SNS.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. Securing multiple major regulatory approvals for a niche biodefense drug is a notable achievement.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High. Each approval requires significant, distinct regulatory submissions and local market engagement.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High. Management has clearly prioritized global market access alongside domestic needs.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. The collection of approvals acts as a barrier to entry for new competitors in those specific jurisdictions.\u003c\/p\u003e\n\n\u003cp\u003eThe global regulatory footprint for TPOXX (tecovirimat) is a key component of its value proposition, extending market reach beyond the U.S. Strategic National Stockpile (SNS) contracts.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eJurisdiction\u003c\/th\u003e\n\u003cth\u003eRegulatory Agency\u003c\/th\u003e\n\u003cth\u003eApproved Indications (TPOXX\/Tecovirimat)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUnited States (US)\u003c\/td\u003e\n\u003ctd\u003eFDA\u003c\/td\u003e\n\u003ctd\u003eSmallpox only\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCanada\u003c\/td\u003e\n\u003ctd\u003eHealth Canada\u003c\/td\u003e\n\u003ctd\u003eSmallpox only\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEuropean Union (EU)\u003c\/td\u003e\n\u003ctd\u003eEMA\u003c\/td\u003e\n\u003ctd\u003eSmallpox, mpox, cowpox, vaccinia complications\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUnited Kingdom (UK)\u003c\/td\u003e\n\u003ctd\u003eMHRA\u003c\/td\u003e\n\u003ctd\u003eSmallpox, mpox, cowpox, vaccinia complications\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eJapan\u003c\/td\u003e\n\u003ctd\u003ePMDA\u003c\/td\u003e\n\u003ctd\u003eSmallpox, mpox, cowpox, vaccinia complications\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eSpecific statistical and financial data points related to international market penetration and approval processes include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eInternational sales recognized in the six months ended June 30, 2025: \u003cstrong\u003e$5.8 million\u003c\/strong\u003e, consisting of a delivery to \u003cstrong\u003eone\u003c\/strong\u003e country.\u003c\/li\u003e\n\u003cli\u003eInternational sales recognized in the six months ended June 30, 2024: \u003cstrong\u003e$11.0 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eTotal overseas earnings from oral TPOXX orders: \u003cstrong\u003e\u0026gt;$135 million\u003c\/strong\u003e from \u003cstrong\u003e\u0026gt;30\u003c\/strong\u003e customers.\u003c\/li\u003e\n\u003cli\u003eTPOXX orders from \u003cstrong\u003e13\u003c\/strong\u003e EU\/EFTA countries in Q4 2023 under a joint procurement framework: approximately \u003cstrong\u003e$18 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe Japanese regulatory approval (TEPOXX) in late 2024\/January 2025 was based on data from \u003cstrong\u003e15\u003c\/strong\u003e clinical trials, which included a repeat-dose Phase I pharmacokinetics trial involving \u003cstrong\u003e20\u003c\/strong\u003e healthy volunteers conducted in Japan.\u003c\/li\u003e\n\u003cli\u003eThe EMA, MHRA, and PMDA approvals cover TPOXX for the treatment of smallpox, mpox, cowpox, and vaccinia complications following vaccination against smallpox.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eSIGA Technologies, Inc. (SIGA) - VRIO Analysis: 7. Specialized Manufacturing Tech Transfer Capability (IV Formulation)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Enhances supply chain resiliency and meets specific government requirements for diverse delivery methods, supported by dedicated funding.\u003c\/p\u003e\n\u003cp\u003eThe U.S. government added \u003cstrong\u003e$14 million\u003c\/strong\u003e in April 2025 to support transferring IV formulation manufacturing to a new contractor under the 19C BARDA contract. As of June 30, 2025, exercised options under the contract provide for payments up to \u003cstrong\u003e$76.8 million\u003c\/strong\u003e for the manufacture of courses of IV TPOXX® (IV FDP).\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. The specific know-how for scaling and transferring the IV formulation process is specialized.\u003c\/p\u003e\n\u003cp\u003eThe base period of performance specifies potential payments of \u003cstrong\u003e$8.0 million\u003c\/strong\u003e for the manufacture of 10,000 courses of IV FDP, of which \u003cstrong\u003e$3.2 million\u003c\/strong\u003e is related to the manufacture of bulk drug substance (IV BDS).\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate. While contract manufacturers exist, the specific tech transfer package and process knowledge are proprietary to SIGA’s experience.\u003c\/p\u003e\n\u003cp\u003eThe estimated gross margin for sales of the IV formulation under current contract terms is \u003cstrong\u003eless than 40%\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High. The company is actively executing this transfer, showing organizational capability in complex manufacturing logistics.\u003c\/p\u003e\n\u003cp\u003eThe company recognized revenues on an over time basis for the three months ended June 30, 2025, of \u003cstrong\u003e$2.0 million\u003c\/strong\u003e, and for the six months ended June 30, 2025, of \u003cstrong\u003e$3.2 million\u003c\/strong\u003e, related to performance obligations under the 19C BARDA Contract.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. Once the tech transfer is complete, the advantage shifts to the new manufacturer, though SIGA retains oversight.\u003c\/p\u003e\n\u003cp\u003eThe following table summarizes key financial aspects related to IV TPOXX® under the 19C BARDA Contract as of June 30, 2025:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eAmount\u003c\/th\u003e\n\u003cth\u003eContext\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Payments Contemplated (IV FDP Manufacture)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$8.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePart of the $79.2 million base period potential payments.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayments for IV BDS Manufacture\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$3.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePortion of the $8.0 million IV FDP manufacture payment.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCumulative IV BDS\/FDP Received\/Set Aside\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$61.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of June 30, 2025, delivered or set aside for the Strategic Stockpile.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExercised Option Payments (IV FDP Manufacture)\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e$76.8 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eMaximum potential payments under exercised options for IV FDP manufacture.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue Recognized (Over Time - 6 Months Ended 6\/30\/2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$3.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eRevenue recognized over time for other performance obligations.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eOrganizational execution is further evidenced by specific contract line item numbers (CLINs) related to the transfer:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCLIN0001 (Contract mod 0018): Tech transfer of previously completed GMP manufacturing to new facility, material procurement, engineering, and process validation batches, regulatory.\u003c\/li\u003e\n\u003cli\u003eCLIN0001 (Funded Base): IV formulation process validation, pediatric formulation development to NDA, pediatric formulation packaging development, pediatric formulation clinical study formulation development, pediatric formulation pharmacokinetic clinical study conduct, regulatory support through pediatric formulation NDA, environmental studies, DDI phosphate binder study conduct, establish BDS CMO backup, labor, material procurement.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eSIGA Technologies, Inc. (SIGA) - VRIO Analysis: 8. Established International Sales Channel\/Customer Base\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Provides a secondary, albeit lumpy, revenue stream and validates TPOXX's utility outside the U.S. They recorded \u003cstrong\u003e$6 million\u003c\/strong\u003e in oral TPOXX sales to an international customer in the first nine months of 2025.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. Having international sales to \u003cstrong\u003e13 countries\u003c\/strong\u003e in 2024, plus a recent commercial sale to \u003cstrong\u003eMorocco\u003c\/strong\u003e, shows established reach.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate. Building relationships with foreign health ministries takes time and trust, which SIGA has cultivated. The agreement to supply TPOXX in \u003cstrong\u003eMorocco\u003c\/strong\u003e marks SIGA's first commercial sale on the African continent.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Moderate. The company is focused on building this channel, though U.S. sales remain dominant. For the nine months ended September 30, 2025, total product sales were \u003cstrong\u003e$85.8 million\u003c\/strong\u003e, with \u003cstrong\u003e$6 million\u003c\/strong\u003e attributed to one international customer.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. International orders can be unpredictable, and new competitors could emerge in specific regions.\u003c\/p\u003e\n\n\u003cp\u003eInternational Sales Performance Metrics:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003ePeriod\u003c\/th\u003e\n\u003cth\u003eAmount\/Count\u003c\/th\u003e\n\u003cth\u003eSource Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOral TPOXX Sales to One International Customer\u003c\/td\u003e\n\u003ctd\u003eNine Months Ended September 30, 2025\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eReported delivery to an international customer.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInternational Sales (Product Sales)\u003c\/td\u003e\n\u003ctd\u003eNine Months Ended September 30, 2024\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$12 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSales to \u003cstrong\u003e12 countries\u003c\/strong\u003e.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInternational Sales (Product Sales)\u003c\/td\u003e\n\u003ctd\u003eFirst Quarter 2024\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eDelivered to \u003cstrong\u003eeight international customers\u003c\/strong\u003e.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInternational Sales (Product Revenue)\u003c\/td\u003e\n\u003ctd\u003eFirst Quarter 2025\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSale to a repeat international customer.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Product Sales\u003c\/td\u003e\n\u003ctd\u003eNine Months Ended September 30, 2025\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$85.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eTotal product sales for the period.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCountries with International Sales\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e13 countries\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eNumber of countries receiving international sales.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eFurther details on international engagement:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eSIGA has received procurement orders for oral TPOXX from \u003cstrong\u003e30 countries\u003c\/strong\u003e over the past three years.\u003c\/li\u003e\n\u003cli\u003eThe company announced its first commercial sale of TPOXX in Africa with the agreement to supply \u003cstrong\u003eMorocco\u003c\/strong\u003e in October 2024.\u003c\/li\u003e\n\u003cli\u003eTPOXX received regulatory approval in \u003cstrong\u003eJapan\u003c\/strong\u003e (as TEPOXX) in January 2025.\u003c\/li\u003e\n\u003cli\u003eInternational sales represented approximately \u003cstrong\u003e$23 million\u003c\/strong\u003e of the total \u003cstrong\u003e$133 million\u003c\/strong\u003e in product sales for the full year 2024.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eSIGA Technologies, Inc. (SIGA) - VRIO Analysis: 9. Focus on Biodefense\/Orthopoxvirus Niche Expertise\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Positions SIGA as the recognized, go-to expert for a critical national security threat, which drives government funding and procurement priority. Their mission is explicitly tied to supporting biodefense preparedness plans.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e High. Few companies maintain this singular, deep focus on a specific, high-consequence, low-frequency threat like smallpox. TPOXX is the \u003cstrong\u003eonly\u003c\/strong\u003e FDA-approved oral antiviral for smallpox.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High. It requires a decade-plus commitment to a therapeutic area that lacks broad commercial appeal. A contract worth over \u003cstrong\u003e$400 million\u003c\/strong\u003e with U.S. BARDA validated TPOXX as a critical component of U.S. national biodefense.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High. The entire corporate structure and R\u0026amp;D pipeline are aligned around this niche. Total revenues for the nine months ended September 30, 2025, were \u003cstrong\u003e$90.8 million\u003c\/strong\u003e (Total Revenues) or \u003cstrong\u003e$86 million\u003c\/strong\u003e (Product Revenues).\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. This specialized knowledge and reputation are deeply embedded and difficult for a generalist pharma company to match quickly.\u003c\/p\u003e\n\u003cp\u003eThe niche expertise is supported by key product and contract milestones:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTPOXX is approved in the United States and Canada for the treatment of smallpox.\u003c\/li\u003e\n\u003cli\u003eTPOXX is authorized in Europe and the UK for treating smallpox, monkeypox, cowpox, and complications from vaccinia.\u003c\/li\u003e\n\u003cli\u003eProduct sales for the nine months ended September 30, 2025, included \u003cstrong\u003e$53 million\u003c\/strong\u003e of oral TPOXX and \u003cstrong\u003e$26 million\u003c\/strong\u003e of IV TPOXX sales under the 19C BARDA contract.\u003c\/li\u003e\n\u003cli\u003eThe company has a history of large procurement contracts, including an order for \u003cstrong\u003e$113 million\u003c\/strong\u003e of TPOXX exercised in July 2024.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eFinance: 13-Week Cash Flow Projection Incorporating Expected 2026 Revenue\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe projection incorporates the expected \u003cstrong\u003e$26 million\u003c\/strong\u003e IV TPOXX delivery revenue targeted for 2026, which relates to an option exercised in March 2025.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Flow Component\u003c\/td\u003e\n\u003ctd\u003eLatest Known Balance \/ Period\u003c\/td\u003e\n\u003ctd\u003eProjected Weekly Inflow\/Outflow (Example Structure)\u003c\/td\u003e\n\u003ctd\u003eNotes \/ Relevant Figure\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBeginning Cash Balance\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$172 million\u003c\/strong\u003e (As of Q3 2025 End)\u003c\/td\u003e\n\u003ctd\u003eWeek 1: $172,000,000\u003c\/td\u003e\n\u003ctd\u003eCash Balance as of Q3 2025 End.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOperating Cash Inflow (Product Sales)\u003c\/td\u003e\n\u003ctd\u003eQ2 2025 Product Revenue: $79.1 million\u003c\/td\u003e\n\u003ctd\u003eWeeks 1-13: Variable based on current order fulfillment rate.\u003c\/td\u003e\n\u003ctd\u003eQ2 2025 Product Revenues.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOperating Cash Inflow (R\u0026amp;D Revenue)\u003c\/td\u003e\n\u003ctd\u003eQ2 2025 Total Revenues: $81.1 million\u003c\/td\u003e\n\u003ctd\u003eWeeks 1-13: Variable based on milestone achievement.\u003c\/td\u003e\n\u003ctd\u003eQ2 2025 Total Revenues.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFuture Contract Revenue (IV TPOXX)\u003c\/td\u003e\n\u003ctd\u003eExpected 2026 Delivery\u003c\/td\u003e\n\u003ctd\u003eN\/A (Scheduled for 2026)\u003c\/td\u003e\n\u003ctd\u003eExpected \u003cstrong\u003e$26 million\u003c\/strong\u003e IV TPOXX delivery revenue in 2026.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Outflow (Operating Expenses)\u003c\/td\u003e\n\u003ctd\u003eQ3 2025 Net Loss: ~$6 million\u003c\/td\u003e\n\u003ctd\u003eWeeks 1-13: Estimated weekly burn rate based on recent loss.\u003c\/td\u003e\n\u003ctd\u003eQ3 2025 Net Loss.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Outflow (Shareholder Returns)\u003c\/td\u003e\n\u003ctd\u003eSpecial Cash Dividend Paid May 2025: $0.60\/share\u003c\/td\u003e\n\u003ctd\u003eWeeks 1-13: Zero unless another dividend is declared.\u003c\/td\u003e\n\u003ctd\u003eSpecial Cash Dividend of $0.60 per share declared April 8, 2025.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEnding Cash Balance (Projected)\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003eCalculated: Beginning Balance + Total Inflows - Total Outflows\u003c\/td\u003e\n\u003ctd\u003eCompany maintains net zero debt.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516250546325,"sku":"siga-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/siga-vrio-analysis.png?v=1740214962","url":"https:\/\/dcf-model.com\/pt\/products\/siga-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}